Dr. Reddy’s extends voluntary recall of antiepileptic drug

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/	gustavofrazao)
(Image: Getty/ gustavofrazao)

Related tags: Dr. Reddy's Laboratories, Dr. reddy, Recall, Label, Statin, Epilepsy, Injection

The voluntary recall, originally initiated due to a product compliant in October 2018 for mislabeling, continues for anti-seizure drug, Levetiracetam injection in single-dose bags.

The pre-printed text content on the infusion bag indicates the product information as Levetiracetam in .75% sodium chloride injection 1000mg/100ml; however, the label on the external foil pouch has the correct product information: Levetiracetam .54% sodium chloride injection 1500mg/100ml.

Levetiracetam injection is an antiepileptic drug indicated for adjunct therapy in adults when oral administration is temporarily not feasible.

No adverse events have been reported in relation to this recall. Patients who may have been administered the mislabeled product could experience adverse reactions such as somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma related to over dosage.

The batch was distributed in the US between August and September 2018. Dr. Reddy’s notified distributors to arrange for return of any recalled product.

It has not be disclosed which company site manufactured the mislabeled products.

Previous recall

Dr. Reddy’s voluntarily recalled 236,000 bottles of statins​ in July 2018, after impurities were found in the products.

All of the recalled medicines were produced at Dr. Reddy’s facility in Srikakulam, India. That facility received a Form 483​ with 13 observations from the US Food and Drug Administration (FDA) in May 2018.

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us


View more